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Nephrotoxicity is within the recognized toxic effects of arsenic. In this study we 
assessed the effect of arsenite on the renal capacity to metabolize and handle 
arsenicals in rats exposed to drinking water with 0, 1, 5, or 10 ppm sodium arsenite for 
ten days. Arsenite treatment did not affect the gene expression of the main enzyme 
catalyzing methylation of arsenite, As3mt, while it reduced the expression of GSTO1 
mRNA and protein. Arsenite decreased the expression of Aqp3, Mrp1, Mrp4, and 
Mdr1b (i.e., transporters and channels used by arsenic), but not that of Aqp7, Glut1, 
Mrp2, and Mdr1a. The protein abundance of AQP3 was also reduced by arsenite. 
Arsenite increased urinary NGAL and FABP3 and decreased Klotho plasma levels, 
without alteration of creatinine, which evidenced early tubular damage. Renal Klotho 
mRNA and protein expressions were also downregulated, which may exacerbate renal 
damage. No effect was observed in selected miRNAs putatively associated with renal 
injury. Plasma PTH and FGF23 were similar between groups, but arsenite decreased 
the renal expression of Fgfr1 mRNA. In conclusion, exposure to arsenite alters the 
gene expression of proteins involved in the cellular handling of arsenical species and 
elicits tubular damage. 
 













Chronic exposure to high levels of arsenic due to contaminated water or food 
sources is a human health problem affecting millions of people in several parts of the 
world (Nordstrom, 2002; World Bank, 2005). Inorganic arsenic – arsenate (AsV) and 
arsenite (AsIII) – is recognized as a multi-target carcinogen (especially in the skin, 
bladder and lungs) (Smith and Steinmaus, 2009, IARC, 2012), and  although strong 
evidence is limited, it has also been associated with a wide range of adverse health 
effects, such as cardiovascular disease (Balakumar and Kaur, 2009; States et al., 
2009), diabetes (Díaz-Villaseñor et al., 2007; Smith, 2013), reproductive disorders 
(Pizent et al., 2012; Sengupta et al., 2015), neurological disorders (Tyler and Allan 
2014), and renal toxicity (Fowler, 2005). 
Several mechanisms of arsenic toxicity have been described, such as interference with 
phosphate and sulfur metabolism, oxidative stress, genotoxicity, interference with 
signal transduction, stimulation of cellular proliferation, and alteration of DNA 
methylation (Hughes et al., 2011; Thomas, 2007). However, the severity of the effects 
depends on the ability of the different cells to manage the incoming concentrations of 
arsenic, and in turn this depends on the rates of uptake, metabolism, and efflux from a 
cell. Most inorganic arsenic enters a cell in the form of AsIII, given that AsV is rapidly 
reduced in the blood to arsenite, at least partially, (Villa-Bellosta and Sorribas, 2008). 
AsIII uptake pathways, in turn, include absorption through the channel proteins, 
aquaglyceroporins (AQP3, 7, 9, and 10), and the equilibrative D-glucose transporter 
(GLUT1) (Mukhopadhyay et al., 2014; Thomas, 2007). In the intestine, however, AsV 
seems to be absorbed through the sodium Pi cotransporter NaPi-IIb (SLC34A2) (Villa-
Bellosta and Sorribas, 2010). Arsenicals then undergo extensive biotransformation 
through conversion into methylated metabolites and through glutathione-driven 
reduction. The trivalent oxidation state forms of arsenic (arsenite, mono-, and di-
methylarsonous acid) are methylated primarily by arsenite methyltransferase (AS3MT, 
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Cyt19), a highly conserved enzyme that transfers the methyl group of S-
adenosylmethionine to the arsenical molecule (Lin et al., 2002; Thomas et al., 2007). 
The resulting methylated pentavalent arsenicals (monomethylarsonic or dimethylarsinic 
acid) are then reduced to trivalent forms in the presence of glutathione, mainly by the 
activity of glutathione S-Transferase Omega 1 (GSTO1) (Zakharyan et al., 2001). The 
efflux of methylated and/or glutathione-conjugated arsenicals out of a cell relies mainly 
on the activity of members of two subfamilies of ATP-binding cassette transporters: 
ABCB (multidrug resistance proteins, MDR) and ABCC (multidrug resistance-
associated proteins, MRP). Specifically, the transporters with demonstrated activity in 
cellular arsenical elimination include ABCB1/MDR1/P-glycoprotein (although it does 
not translocate glutathione-conjugates), ABCC1/MRP1, ABCC2/MRP2, and 
ABCC4/MRP4 (Banerjee et al., 2014; Leslie, 2012). 
Arsenic is also a recognized nephrotoxic metalloid that triggers diverse events 
inside cells (e.g., intracellular glutathione depletion, activation of the caspase-3 and -9 
pathways, p53-mediated apoptosis), which will ultimately lead to tubular injury (Robles-
Osorio et al., 2015; Zheng et al., 2014). Long-term arsenic exposure has been recently 
associated with the development of a fibrotic phenotype in human kidney cells, 
probably mediated by DNA methylation (Chang and Singh, 2019).  In rats treated with 
arsenate or dimethylarsinic acid, the highest concentrations of dimethylated arsenic 
were found in the blood, and similar values were observed in the kidney, liver, and 
lungs (Adair et al., 2007), thereby supporting the notion that the kidney is the primary 
target organ of arsenic toxicity.  
The present work focusses on the effects arsenic exposure in the kidney.  The aim 
of this study was to assess if arsenic exposure in rats altered the expression of 
proteins involved in the uptake, metabolism, and efflux of arsenicals in renal cells and if 
these changes could be related, at least in part, to nephrotoxicity. We found evidence 
of alteration of the gene expression of proteins involved in the cellular handling of 
arsenical species, as well as evidence of the early biomarkers of kidney damage. 
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Given the pivotal role of the kidneys in the homeostasis of inorganic phosphate and in 
the interactions of arsenic at different levels, we also investigated the effects of oral 
arsenite on the renal handling of Pi. 
 
 
2. Materials and methods 
 
2.1. Animal experimentation  
All procedures were in accordance with European and Spanish legislation and 
were approved by the Ethical Committee for Animal Experiments of the University of 
Zaragoza. 
Two-month old male Wistar rats (Janvier Labs, Saint Berthevin Cedex, France) 
were exposed to tap water with 0, 1, 5, or 10 ppm NaAsO2 (sodium arsenite) for 10 
days (4 animals per group). This experiment was performed twice with identical results, 
and therefore only one is shown. The doses were chosen considering that rats are less 
susceptible to arsenical toxicity than humans and other animal species (ATSDR, 2007; 
NRC, 1977). To estimate the actual arsenic intake, water consumption was measured 
every three days, and the rats were weighed at the beginning and end of the 
experiment. The concentration of arsenic in the tap (municipal) water is below the 
analytical detection level and much lower than the 10 ppb recommended limit. Animals 
were also fed a synthetic, arsenic-free food containing 0.6% inorganic phosphate 
(SAFE Diets, Augy, France) used in previous studies (e.g. Hortells et al., 2017). 
On day 9, urine was collected for 24 h (with normal food and water treatments), after 
which the rats were anesthetized (day 10) taking one animal from each group in a 
rotating manner to avoid diurnal variations. Heparinized blood samples were collected 
from the abdominal aorta in order to measure blood gases and to obtain plasma by 
centrifugation. After being sacrificed, ice-cold renal medulla and the cortex were 
separated by quick manual dissection, frozen with liquid nitrogen, and stored at -80º C 
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until analyzed. In this work only kidney cortex sections were used because it expresses 
all known transporters for the different arsenical species. 
 
2.2. Plasma and urine determinations 
Blood gases and electrolytes (Na+, K+, Cl–, pH, PCO2, PO2, tHb, SO2, tCO2, HCO3–, 
base excess, anion gap) were measured in a VetStat® system (IDEXX Laboratories, 
Westbrook, ME, USA). Plasma and urinary creatinine, Pi, and urea were determined by 
colorimetric kits (BioAssay Systems, Hayward, CA, USA), and total urinary protein was 
measured by a BCA Protein Assay reagent. Enzyme-linked immunosorbent assays 
were performed to determine urinary neutrophil gelatinase-associated lipocalin (NGAL) 
and fatty acid-binding protein 3 (FABP3, both from Elabscience Biotechnology, Wuhan, 
China), in addition to plasma intact parathyroid hormone (PTH, Immutopics, San 
Clemente, CA, USA), Klotho (BlueGene, Shanghai, China), and fibroblast growth factor 
23 (FGF23, Kainos Laboratories, Tokyo, Japan). 
 
2.3. mRNA and miRNA expression analysis 
Total RNA was isolated from renal cortices using the Quick-RNA MiniPrep Kit 
(Zymo Research, Irvine, CA, USA), and complementary DNA was prepared from 1 μg 
of total RNA using the PrimeScript RT Reagent kit (Takara Clontech, Mountain View, 
CA, USA). All qPCR reactions were performed using SYBR Premix Ex Taq II (Takara) 
on a LightCycler 1.5 (Roche Applied Science, Mannheim, Germany). The primer 
sequences are presented in Table 1. For relative quantification, gene expression was 
normalized to both an endogenous control (acidic ribosomal phosphoprotein P0, Arbp) 






Gene Accession no. Sense Antisense Range 
As3mt NM_080890.1 TTCGCCTCTTCAAACTCCC TCCTCATCCACTTCAACAGC 809-953 
Gsto1 NM_01007602 AGCCCGAGTGGTTCTTTGAG TGCTTCATCCAGGTACTCGC 258-370 
Aqp3 NM_031703.1 AGGCAGAGAATGTGAAGCTG AGTCAGTGGACACTCAAGAGA 906-1014 
Aqp7 NM_019157.2 CACCCACAATTCCACAATGG ATATGAGCCACGGAACCAAG 246-386 
Glut1 NM_138827.1 TGATTGGTTCCTTCTCTGTGG CCCAGGATCAGCATCTCAAAG 438-582 
Mrp1 NM_022281.2 TCATCATCCTACTGGCTACGC CGAGAGGAGGCCACATAGAA 3359-3455 
Mrp2 NM_012833.2 GCTGGATCTGGTACTGAAAGG TGAAGAGGCAGTTTGTGAGG 4137-4246 
Mrp4 NM_133411.1 GTATGGTGCTGTCCGGTTGA TCTTGATCCTCCGAACGCTG 1071-1162 
Mdr1a NM_133401.1 GTTTCGCTATGCAGGTTGGC AAGTGGGAGCGCAATTCCAT 199-283 
Mdr1b NM_012623.2 TGCTGTTGGCATATTCGGGA CGTGGATGATAGCAGCGAGA 125-213 
Fgfr1 NM_024146.1 CGTGGAGTTCATGTGCAAGG TACGGCAAGTTGTCTGGACC 816-920 
Klotho NM_031336.1 TTTAGGGCGGCTCAGAAAGG TCTCCGCCACTTCTTTGTCC 2176-2275 
NaPi-IIa NM_013030.1 CTCACTGGTGTTTGGCATTTC AACAAGCACCACGAAGGC 1628-1721 
Arbp NM_022402.2 CACCTTCCCACTGGCTGAA TCCTCCGACTCTTCCTTTGC 844-971 
 
Table 1. Primer sequences used for mRNA expression analysis by real time PCR. 
As3mt, arsenite methyltransferase; Gsto1, glutathione S-transferase omega 1; Aqp3 
and 7, aquaporin 3 and 7; Glut1, glucose transporter 1; Mrp1, 2, and 4, multidrug 
resistant proteins 1, 2, and 4; Mdr1, multidrug resistant protein/P-glycoprotein; Fgfr1, 
fibroblast growth factor receptor 1; NaPi-IIa, sodium-dependent phosphate transporter 
type II isoform a; Arbp, acidic ribosomal phosphoprotein P0. 
 
Enriched micro RNA (miRNA, miR) preparations from the renal cortices were 
obtained with the PureLink™ miRNA Isolation Kit (Thermo Fisher, Waltham, MA, USA), 
and they were reverse-transcribed using the microScript microRNA cDNA Synthesis Kit 
(Norgen Biotek Corp., Ontario, Canada). The cDNA obtained was diluted and used as 
a template in a qPCR reaction to analyze the relative expression of several rat miRNAs 
associated with renal damage: rno-miR-21, rno-miR-132, rno-miR-200c, and rno-miR-
423. Both the 5p and 3p arms of each miRNA were determined, and the results were 
normalized to 5S ribosomal RNA (5S rRNA) and to a calibrator. The primer sequences 
are presented in Table 2.  
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rno-mir-423-3p  AGCTCGGTCTGAGGCCCCTCAGT 
5S ribosomal RNA NR_033176.2 CCCGATCTCGTCTGATCT 
 
Table 2. Primer sequences used for the detection of rat micro RNAs by real-time PCR. 




Total protein from the renal cortex was extracted by treatment with 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% 
SDS, 0.5% deoxycholate, 1% Triton X-100, and protease inhibitor cocktail, Sigma-
Aldrich) and was quantified using a BCA Protein Assay reagent. Western-blots were 
performed by overnight incubation of PVDF membranes with polyclonal antibodies 
raised against rat Klotho, MDR1, AQP3 (Biorbyt, Cambridge, UK), and GSTO1 
(Thermo Fisher), at concentrations of 3.3, 2, 0.5, and 1.8 ug/mL, respectively. The 
signal was detected by chemiluminescence and quantified using a Versadoc MP 





2.5. Statistical analyses 
The comparison between groups was performed by one-factor analysis of variance 
(ANOVA) followed by a Dunnet’s multiple comparison test, using GraphPad Prism 5. 
Data are presented as the mean ± SE. The level of significance was considered to be 




3.1. Arsenic intake 
No overt signs of toxicity were observed throughout the study, and there were no 
differences in the weight gain between groups at the end of the experiment. Water 
intake (measured every two days and averaged over 10 days) was less in the 10-ppm 
group than in the control group (32.7 ± 1.8 mL vs 65.4 ± 19.6 mL), although it did not 
reach a statistical significance. However, that lower water intake resulted in a lower 
than expected arsenite intake in the 10-ppm group. The average arsenite intake 
calculated per rat per day is presented in Table 3. Accordingly, the twenty-four hour 














Table 3. Urinary and plasma parameters in rats treated with 0 (control), 1, 5, and 10 
ppm of sodium arsenite for 10 days.  
Means with different superscripts are different, P < 0.001. 
 
 
3.2. Effects of exposure on the transport and metabolism of arsenicals 
The gene expression of proteins involved in the metabolism and transport of 
arsenicals in the cells was evaluated by real time RT-PCR. Arsenite treatment did not 
affect the gene expression of the main enzyme that catalyzes the methylation of 
arsenite, As3mt, while it did reduce the expression of another relevant enzyme 
involved in the detoxification of arsenicals, Gsto1 (P < 0.05, Fig. 1). As for the proteins 
involved in the influx of arsenicals, arsenite did not change the expression of Glut1 and 
Aqp7, but it did reduce the expression of Aqp3 to a similar extent at all doses (P < 0.05, 
Fig. 1). Arsenite treatment distinctly affected the proteins participating in the efflux of 
arsenicals from the cell: it reduced Mrp4 at all concentrations (P < 0.05), and the same 
trend was observed in Mrp1 at 5 and 10 ppm (P < 0.1), while the gene expression of 
Mrp2 remained unchanged. The two isoforms of Mdr1 (a and b) were measured: 
 Control 1 ppm AsIII 5 ppm AsIII 10 ppm AsIII 
Calculated  AsIII intake 
(µg/rat/day) 0 56.3 ± 9.7 267.4 ± 34.4 326.4 ± 17.7 
Water intake 
(mL/rat/day) 65.4 ± 19.6 56.3 ± 9.8 53.5 ± 6.9 32.7 ± 1.8 
Plasma parameters 
Creatinine (mg/dL) 0.45 ± 0.02 0.41 ± 0.02 0.44 ± 0.02 0.37 ± 0.03 
Pi (mM) 1.50 ± 0.2 1.75 ± 0.1 1.82 ± 0.05 1.68 ± 0.11 
Urea (mg/dL) 38.7 ± 3.2 31.9 ± 6.5 33.0 ± 3.1 35.2 ± 4.4 
Urinary parameters 
24-hour urine volume 
(mL) 12.7 ± 0.8
a 13.5 ± 0.1a 11.9 ± 1.0a 8.6 ± 0.1b 
Creatinine (mg/dL) 66.9 ± 12.4 56.4 ± 4.0 72.3 ± 8.1 80.7 ± 10.9 
Pi/Creatinine 0.45 ± 0.10 0.38 ± 0.08 0.46 ± 0.04 0.46 ± 0.11 
Urea/Creatinine 0.048 ± 0.008 0.043 ± 0.009 0.043 ± 0.009 0.043 ± 0.006 
Protein/Creatinine 0.18 ± 0.03 0.16 ± 0.03 0.19 ± 0.01 0.15 ± 0.03 
GFR (mL/min) 1.10 ± 0.10 1.12 ± 0.17 1.07 ± 0.03 1.14 ± 0.15 
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Arsenite did not affect Mdr1a mRNA expression, but it tended to reduce Mdr1b at 1 
and 10 ppm (P < 0.1, Fig. 1).  
 
 
Figure 1. Effect of arsenite on the gene expression of proteins involved in 
arsenic metabolism. Rats were treated with 0 (control), 1, 5, and 10 ppm of sodium 
arsenite in water for 10 days. Gene expression (relative to Arbp) in renal cortex. 
Asterisks indicate difference from the control after Dunnet’s posttest (*P < 0.05, **P < 
0.01, #P < 0.1). As3mt, arsenite methyltransferase; Aqp3 and 7, aquaporin 3 and 7; 
Glut1, glucose transporter 1; Gsto1, glutathione S-transferase omega 1; Mrp1, 2, and 
4, multidrug resistant proteins 1, 2, and 4; Mdr1, multidrug resistant protein/P-
glycoprotein. 
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To assess if the changes observed in gene expression were parallel to protein 
expression, Western blots of some of the AsIII-altered genes were carried out in 
protein extracts from the renal cortex. The protein abundance of GSTO1 tended to 
decrease with 1 ppm AsIII (P = 0.8) and was significantly reduced at 5 and 10 ppm (P 
< 0.05, Fig. 2). Similarly, AQP3 was also reduced at 5 and 10 ppm (P < 0.05), while no 
effect could be detected on MDR1 protein expression (Fig. 2).  
 
 
Figure 2. Effect of arsenite on the abundance of proteins involved in arsenic 
metabolism. Rats were treated with 0 (control), 1, 5, and 10 ppm of sodium arsenite in 
water for 10 days. Representative Western blots of selected proteins (relative to β-
actin). Asterisks indicate difference from the control after Dunnet’s post test (*P < 0.05, 
#P < 0.1). AQP3, aquaporin 3; GSTO1, glutathione S-transferase omega 1; MDR1, 





3.3. Effects on renal function 
The parameters measured in urine and plasma were used to evaluate renal 
function. No effect by arsenite intake on the concentrations of creatinine, urea, or 
phosphate was observed, either in the plasma or urine (Table 3). The calculated 
glomerular filtration rate was also similar between groups. The analysis of blood gases 
and pH did not provide evidence any alteration due to the arsenite treatment (data not 
shown). 
After treatment with AsIII at 5 and 10 ppm, the urinary concentrations of the two 
early markers of acute renal damage, NGAL and FABP3, revealed approximate 
increases of 2- and 7-fold with respect to the control, respectively (P < 0.05, Fig. 3A). 
Four micro RNAs related to kidney damage were determined, in both the 3p and 5p 
arms. While some of them could not be detected in the renal cortex, we were able to 
quantify mir-21-5p, mir-200c-3p, and mir-423-3p, revealing that arsenite treatment did 




Figure 3. Arsenite causes renal damage. Rats were treated with 0 (control), 1, 5, and 
10 ppm of sodium arsenite for 10 days. A, Urinary concentrations of neutrophil 
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gelatinase-associated lipocalin (NGAL) and fatty acid-binding protein 3 (FABP3). B, 
MicroRNA expression in the renal cortex (relative to 5S rRNA). Asterisks indicate 
difference from the control after Dunnet’s posttest (*P < 0.05). 
 
3.4. Effects on Pi homeostasis 
Despite the apparent absence of an effect by arsenite on the renal handling of Pi, 
we also checked the effect on the plasma concentrations of several Pi-related 
hormones: PTH, soluble Klotho, and FGF23. The plasma concentrations of PTH and 
FGF23 were similar between groups. Klotho plasma levels decreased by 23% in the 1-
ppm group (P < 0.05) and by 35% in the 5- and 10-ppm groups (P < 0.01) with respect 
to the control (Fig. 4A).  
Klotho and Fgfr1 mRNA in the kidney cortex was significantly less abundant in all 
AsIII-treated groups than in the control group, in a dose-independent manner (P < 
0.001 and P < 0.05, respectively, Fig. 4B). No effect of arsenite treatment was 
observed in the expression of NaPi-IIa. Furthermore, the protein expression of Klotho 






Figure 4. Effect of arsenite on Pi homeostasis. Rats were treated with 0 (control), 1, 
5, and 10 ppm of sodium arsenite for 10 days. A, Plasma concentrations of parathyroid 
hormone (PTH), fibroblast growth factor 23 (FGF23), and Klotho. B, Gene expression 
(relative to Arbp) in the renal cortex. C, Western blot and intensity histogram of Klotho 
(relative to β-actin) in the renal cortex. Asterisks indicate difference from the control 
after Dunnet’s posttest (*P < 0.05, **P < 0.01, ***P < 0.001). PTH, parathyroid 
hormone; FGF23, fibroblast growth factor 23; NaPi-IIa, sodium-dependent phosphate 




The cytotoxic effects of AsIII have been associated with the metabolism and 
accumulation of AsIII in the cell. Entry by arsenite into the cell is facilitated by some 
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aquaporins and hexose transporters (Liu, 2010; Liu et al., 2006). In addition to being 
permeable to water, aquaporins 3, 7, 9, and 10 –the so-called aquaglyceroporins– 
allow entry by small nonionic molecules such as glycerol and urea, and they are 
essential in the homeostasis of metalloids (Bienert, et al. 2008; Liu, 2010). Of these 
aquaporins, we measured the expression of AQP3 and 7 since they are expressed in 
the kidney. In our study, the arsenite-treated rats presented 3-fold lower renal 
expression of Aqp3 mRNA than the controls, and no effect was observed for Aqp7 
abundance. Accordingly, AQP3 protein expression was also reduced, but the effect 
was lower than on the RNA and at the highest concentrations of arsenite. Experiments 
with null mice have shown that AQP3 plays a relevant role in water reabsorption, given 
that AQP3-null mice presented polyuria and a lower capacity to concentrate urine, 
whereas AQP7-null mice maintained the concentration capacity but with increased 
glycerol in urine (Matsuzaki et al., 2017). We did not observe any effect on urine 
concentration (i.e., urinary creatinine levels were similar), which is consistent with a 
modest effect on the protein expression of AQP3 under our experimental conditions. 
On the other hand, due to its involvement in glycerol transport, AQP3 deficiency has 
also been related to impaired lipid biosynthesis and glycerol metabolism, which 
ultimately lead to reduced cell proliferation (Michalek, 2016). 
The exact participation of AQP3 in the transport of arsenicals is not clear. It has been 
demonstrated that, in an aqueous solution and at physiological pH, the predominant 
form of inorganic arsenic is arsenic trioxide (As(OH)3) (Ramírez-Solís, et al. 2004) and 
that human AQP3 (hAQP3), unlike hAQP7 and 9, does not show a significant uptake of 
73As(OH)3 when expressed in oocytes (Liu et al., 2004). In mammals, a proportion of 
arsenite is methylated to mono-, di-, and tri-methylated products, mainly in the liver, but 
when compared to AQP7, AQP3 also does not seem to play a significant role in the 
transport of methylated forms (Liu, 2010).  
Mammalian hexose transporter GLUT1 (SLC2A1) has also been shown to facilitate 
the uptake of trivalent arsenicals when expressed in biological systems in vitro, and 
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indeed it is believed to represent the main entrance route for arsenite in erythrocytes 
and brain epithelial cells, where aquaglyceroporins are not abundantly expressed (Liu 
et al., 2006). GLUT1 is highly expressed in most tissues, and in the kidney it is 
localized to the basolateral membrane of the proximal straight tubules (Augustin, 
2010). Therefore, we also assessed its possible regulation by arsenite, but none of the 
AsIII doses used in our study had any effect on Glut1 mRNA expression. 
The efflux of methylated arsenic from the cell occurs primarily through multidrug 
resistant proteins, members of the ATP-binding cassette (ABC) transporters, sub-
families B and C (i.e. MRP1, 2, and 4 and MDR1/P-glycoprotein) (Leslie, 2012). In this 
study, arsenite treatment reduced the gene expression of Mdr1b, Mrp1, and Mrp4 (Fig. 
1). Even though the protein level of MDR1 was still unchanged during the 10-day 
interval, the changes in the level of mRNA expression suggest an impairment in the 
clearance of arsenical forms out of the cell at longer exposure times. In renal cells, 
MRP4 and MDR1 are localized to the apical (brush border) membrane, and MRP1 is 
localized to the basolateral membrane (Launay-Vacher et al., 2006; van Aubel et al., 
2002). Therefore, the outflow of arsenicals from the cells would be reduced, 
consequently enhancing the susceptibility of the cells to the toxic effects of arsenic. 
Indeed, the number or activity of multidrug resistance proteins has been directly 
associated with cellular tolerance or sensitivity to the toxic effects of arsenic (Thomas, 
2007).  
Two isoforms of MDR1/P-glycoprotein have been described for rodents, encoded 
by genes Mdr1a (Abcb1a) and Mdr1b (Abcb1b), and under certain circumstances they 
have been shown to play dissimilar functions in different organs or to respond 
differently to the same stimulus (Koehn et al., 2019; Su et al., 2017; Zhang et al., 
2019). In our study, only Mdr1b RNA was affected by the AsIII treatment, whereas 
Mdr1a remained unchanged. Coincidently, Abcb1b mRNA also decreased in the renal 
cortices of rats exposed to vitamin D deficiency, with no changes observed in Abcb1a 
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(Wang et al., 2015), but the physiological relevance of this unequal regulation between 
both isoforms has not been explained. 
The detoxification of arsenic in the cell involves several reduction and methylation 
reactions and subsequent efflux out of the cell. The methylation of the trivalent 
oxidation states of arsenic is mainly catalyzed by AS3MT (Lin et al., 2002), which 
produces methylated pentavalent arsenicals that are substrates for the reducing 
activity of GSTO1 (Zakharyan et al., 2001). We have found that treatment with arsenite 
does not alter the gene expression of renal As3mt, whereas it does reduce both Gsto1 
gene expression by around 50% in a dose-independent manner (Fig. 1) and protein 
abundance (Fig. 2). We did not measure the activity of the enzyme, but treatment with 
5 mg/kg arsenate during 4 weeks reduced the renal glutathione-S-transferase activity 
in rats (Miltonprabu et al., 2017). This could imply the accumulation of methylated 
pentavalent forms inside the cell, thereby causing nephrotoxicity. 
To our knowledge, this is the first time that alterations in the proteins involved in 
arsenical metabolism due to arsenite treatment in vivo have been reported. These 
results shed light on the possible mechanisms by which arsenite causes nephrotoxicity, 
and they also have far-reaching implications for therapeutic purposes. Multidrug 
resistant proteins in the renal tubules participate in the urinary excretion of a myriad of 
organic molecules, including xenobiotics and drugs, and therefore the implications of 
the alterations caused by arsenite described here extend to pharmacokinetics, drug 
efficacy, and the manifestation of adverse effects. 
Given that the changes exerted by arsenite in the detoxification system of renal cells 
indicated that the handling and elimination of arsenicals was impaired, we decided to 
evaluate the possible renal damage. Under the present conditions of dose and 
exposure time, arsenite treatment did not affect the plasmatic concentrations of 
creatinine or urea or the urinary levels of creatinine, urea, or protein. Consistently, the 
glomerular filtration rate was similar between groups. According to these results, major 
renal damage could be ruled out. This is in contrast to some works clearly showing 
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renal damage by arsenic in humans (Meliker et al., 2007, Robles-Osorio et al., 2015), 
even in rodents (Shahid et al., 2014, Riaz et al., 2020), but the experimental design 
and epidemiology in humans have, sometimes, provided conflicting results (Samelo et 
al., 2020). However, it is known that these classical endpoints are not sensitive enough 
to detect early renal damage (Sabbisetti and Bonventre, 2012), and several molecules 
occurring in urine in the very early stages of renal injury have been found to be useful 
as biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury 
molecule 1 (KIM-1), N-acetyl-β-D-glucosaminidase (NAG), liver fatty acid binding 
protein (L-FABP), heart fatty acid binding protein (H-FABP, also known as FABP3), 
tissue inhibitor metalloproteinase-2 (TIMP-2), insulin-like growth factor binding protein 
7 (IGFBP-7), clusterin, and netrin, among others (Griffin et al., 2019; Schaub, 2016). 
We have shown that these biomarkers also apply to the renal damage caused by 
arsenite and that rats treated with 5 and 10 ppm of arsenite had increased 
concentrations of both of NGAL and FABP3 in urine when compared to non-treated 
rats. NGAL (also known as lipocalin 2) is a 25-kDa glycoprotein that is present in 
plasma and is bound to metalloproteinase-9 from neutrophils. It is also expressed at 
very low levels in various tissues of the body, but it is readily inducible by injury in 
epithelial cells, including those from the kidneys, liver, and lungs (Mishra et al., 2003). 
Plasma NGAL is filtrated in the glomerulus and is reabsorbed in the proximal tubules, 
and therefore any urinary excretion of NGAL is assumed to be derived from a proximal 
tubule injury that precludes reabsorption and/or increases de novo synthesis 
(Devarajan, 2010). Urine NGAL is among the most promising early biomarkers of acute 
kidney injury, preceding the appearance of other urinary markers (Griffin et al., 2019). 
Fatty acid binding proteins, in turn, are nine 15-kDa molecules localized in the 
cytoplasm of almost all cell types. Heart fatty acid binding protein (or FABP3) is 
abundantly expressed in cardiomyocytes and, to a much lesser extent, also in muscles, 
distal tubular renal cells, the brain, the mammary glands, and the placenta. Unless 
there is an ongoing cardiomyopathy, the presence of FABP3 in urine reflects distal 
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tubular damage (Pelsers, 2008), and it has proved to be a good marker of early renal 
injury (Hofstra et al., 2008; Kokot, et al. 2014). In a rat model of diabetic nephropathy, 
FABP3 showed an early and dramatic rise together with other early biomarkers (Alter 
et al., 2012). 
Several micro-RNAs have also been used as early biomarkers of renal damage. 
Micro-RNAs are short (~22 nucleotides), noncoding RNA molecules that have 
regulatory functions over the expression of their multiple target messenger RNAs 
(Bartel, 2004). They participate in multiple biological processes and have also been 
related to several pathological conditions, including those that affect the kidney (Bhatt 
et al., 2016; Ichii and Horino, 2018). In a screening study of more than 1800 urinary 
miRNAs, miR-21, miR-200c, and miR-423 were identified as the most sensitive 
markers of acute kidney injury in human patients (Ramachandran et al., 2013). In a rat 
tubular injury model induced by ischemia/reperfusion, miR-21 was upregulated in 
kidney cortices (Saikumar et al., 2012). By contrast, we have found no effect of 
arsenite treatment on the expressions of miR-21, miR-200, and miR-423. Likewise, in a 
study performed on a population of children exposed to arsenic, Cárdenas-González et 
al. (2016) did not find any association with these three miRNAs, even if they showed 
signs of early renal damage (i.e., increased KIM-1 levels). Therefore, the 
circumstances that lead to the upregulation of these miRNAs in renal damage are still 
to be elucidated, as it is the role of other miRNAs and their corresponding target 
proteins.  
Arsenite treatment significantly reduced soluble Klotho at all doses (Fig. 4A). 
Klotho mRNA expression in the renal cortex paralleled the Klotho plasma 
concentrations, and it was also accompanied by a reduction in the renal concentration 
of Klotho protein, although this effect was only observed in the group treated with the 
highest concentration of arsenite (Fig. 4B and C). This is in accordance with the lower 
Klotho plasma concentrations, given that the kidney is thought to be the major source 
of soluble Klotho in rodents. It also plays an active role in the development of renal 
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injury. A study by Hu et al. (2010) found that a drop in Klotho levels in plasma and the 
kidney preceded an increase in NGAL and that this parameter was the first one to 
change after ischemia-reperfusion injury in rats. Moreover, not only is antiaging Klotho 
a useful marker, it also prevents renal damage, which is exacerbated when the Klotho 
concentration is reduced (Hu et al., 2012). 
Overall, according to the observed results showing constant creatinine, conserved 
GFR, and high urinary biomarkers (i.e., NGAL and FABP3), the pathophysiological 
condition of these arsenite-treated rats would be early tubular damage, both proximal 
and distal, without excretory dysfunction (for instance, subclinical acute kidney injury) 
(Desanti De Oliveira, et al. 2019; Schaub, 2016).  
Acute kidney injury and chronic kidney disease are associated with alterations of 
the renal handling of phosphate, which ultimately leads to hyperphosphatemia, so we 
set out to investigate if the phosphate balance was disrupted. In our study, the arsenite 
treatment did not alter either phosphatemia or the renal gene expression of the 
phosphate cotransporter NaPi-IIa, which is probably because of the early stage of renal 
injury caused by the arsenite. 
Nevertheless, we wanted to investigate the endocrine milieu that ultimately 
controls phosphate homeostasis. Both PTH and FGF23 are phosphaturic hormones, 
and an increase in their concentrations in plasma is a constant observation in renal 
failure, both in human patients and animal models (Jacquillet and Unwin, 2019). In this 
work, PTH and FGF23 were not affected by arsenite treatment at any dose, consistent 
with normophosphatemia in the animals of this study.  
FGF23 actions are exerted in the kidney through the FGFR1 receptor, but only 
after the binding of FGF23 to Klotho (Urakawa et al., 2006), so target tissue sensitivity 
should be assessed in terms of both the specific receptor expression and Klotho levels, 
which are reduced upon arsenite exposure. It is notable that the gene expression of 
Fgfr1 was also consistently reduced by arsenite, which, in conjunction with the lower 
Klotho concentrations, could imply a resistance of kidney tubular cells to FGF23. On 
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the other hand, the detailed repercussions of the lower expression of renal FGFR1 are 
immeasurable, yet they definitely exceed phosphate homeostasis, given that fourteen 
of the eighteen FGFs bind FGFR1, most of them without the need for the co-receptor 




The interpretation of this set of data is complex, since there are many players in 
the detoxification of arsenical forms, with varying contributions depending on several 
aspects, such as the degree of methylation and/or the glutathione conjugation of the 
arsenical and several other levels amenable to regulation (e.g. epigenetic marks, post-
transcriptional or post-translational changes, enzymatic activity, etc.). However, the 
results presented here support the influence of arsenite on its particular detoxification 
system, which in general terms leads to lower metabolism and lower clearance out of 
the renal cell. This could lead to the accumulation of arsenical forms in the cell, thereby 
increasing cytotoxicity, which is reflected by the increase in the early kidney damage 
markers (i.e., NGAL, FABP3) observed in our study. 
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